Solute carrier family 11 member a1 (Slc11a1; formerly Nramp1/Ity/Lsh/Bcg) encodes a late endosomal/lysosomal protein/divalent cation transporter that regulates iron homeostasis in macrophages (reviewed in references 8, 10, and 17). Slc11a1 was originally mapped (14, 27, 41) and positionally cloned (48) on the basis of its ability to regulate resistance and susceptibility to a range of intramacrophage pathogens, including Salmonella enterica serovar Typhimurium (42) , Leishmania donovani (13) , and Mycobacterium bovis BCG (27) . During macrophage activation, Slc11a1 has multiple pleiotropic effects, including quantitative differences in major histocompatibility complex (MHC) class II expression (4, 31, 32, 51, 52) and in processing of antigen for presentation to T cells (39) . The downstream effect of this pleiotropy in vivo is a bias in immune response toward Th1 in mice carrying the Slc11a1 wild-type allele and toward Th2 in mice carrying the mutant allele (31, 34, 38, 45) . Although a Th1 response is usually of benefit in resistance to infection with intracellular macrophage pathogens (31, 34, 38, 45) , it can be detrimental in chronic infections (19) and contributes to the development of type 1 diabetes (33) . In previous studies Slc11a1 has been shown to be expressed in granules of polymorphonuclear leukocytes (18, 20) and late endosomes and lysosomes of macrophages (28, 44) , but expression in dendritic cells (DCs) has not been reported. Given the importance of DCs in priming T-cell responses and the influence of Slc11a1 on antigen-presenting cell function in macrophages, it was of interest to determine whether Slc11a1 is expressed in, and has similar influences, on DC function. Here we report on the expression and role of Slc11a1 in modulating cytokine transcription, class II expression, and antigen-presenting cell function in CD11c-positive (CD11c ϩ ) bone marrow-derived DCs from Slc11a1 congenic mouse strains.
MATERIALS AND METHODS
Mice. Congenic N20 B10.L-Lsh (Lsh ϭ Nramp1 ϭ Slc11a1) were bred inhouse (11) following 20 generations of backcrossing the Slc11a1 wild-type allele from C57L mice onto a C57BL/10ScSn (B10) background. These are congenic with Slc11a1 mutant B10 mice except for the ϳ10-Mb interval distal to D1Mit80 and proximal to D1Mit44 on chromosome 1 that carries the Slc11a1 gene. BALB/c (BALB) Slc11a1mutant mice and their congenic C.D2-Vil6 Slc11a1 wild-type counterparts were bred in-house. Their derivation is as previously described (40) , with C.D2-Vil6 carrying a congenic interval of ϳ1. 5 Mb from Tnp1 to Vil1 derived from DBA/2 mice. Mice were bred and maintained under specific-pathogen-free conditions. All breeding and procedures were carried out under license and United Kingdom Government Home Office regulations.
Slc11a1 transfected cell lines. RAW264.7 macrophage cell lines stably transfected with wild-type (clones 7.5R and WT3) or mutant (clones 10S and MUT12) alleles at Slc11a1 were made in our laboratory as previously described (6, 49) . The RAW264.7 macrophage cell line has an endogenous copy of the mutant allele from which the protein is expressed at low level (44) through mis-targeting and degradation (49) . The presence of the transgene was verified by sequencing across the mutation site using primers that distinguished the intronless transgene from the endogenous genomic allele. RAW264.7 cell lines were maintained in 25-cm 2 tissue culture flasks in RPMI 1640 supplemented with 10% fetal calf serum (Life Technologies), 50 U of penicillin/ml, 50 g of streptomycin/ml, and 2 mM L-glutamine (hereafter referred to as complete RPMI).
Bone marrow-derived macrophages and DCs. DCs and macrophages were derived from proliferating mouse bone marrow progenitors from Slc11a1 mutant (B10 or BALB) or wild-type (B10.L-Lsh or C.D2-Vil6) mice as indicated in the text, legends, and figures. Bone marrow was taken from femurs and tibia of 6-to 10-week-old mice. Macrophages were cultured in 95-mm bacteriological dishes (1 ϫ 10 7 to 3 ϫ 10 7 cells/dish) in complete RPMI, supplemented with 1 M 2-mercaptoethanol (Life Technologies), 25 mM HEPES (Sigma), and 30% L-cell supernatant (derived from L929 mouse fibroblasts). Culture medium was renewed after 5 days, and cells were used between days 10 and 15. DCs were cultured in flat bottomed six-well plates (1 ϫ 10 6 to 3 ϫ 10 6 cells/well). The culture medium was complete RPMI, supplemented with 1 M 2-mercaptoethanol, 25 mM HEPES, 20 ng of recombinant interleukin-4 (rIL-4)/ml, and 10 ng of rGM-CSF/ml (Peprotech). Half of the culture medium was renewed at days 2, 5, and 9. DCs were recovered from day 5 onward. At day 9, nonadherent DCs were separated by transfer into new six-well dishes. DCs were supplemented with new media and cytokines on alternate days and utilized between days 10 and 15. To demonstrate purity, DCs were labeled with anti-mouse CD11c-fluorescein isothiocyanate (FITC) monoclonal antibody HL3 (MAb HL3; BD Pharmingen) at a 1/200 dilution and analyzed by flow cytometry (FACScan; Becton Dickinson).
Quantification of MHC class II and CD40 expression. Quantification of MHC class II molecules and CD40 expressed on the plasma membrane of macrophages and DCs was performed on live cells by flow cytometry. Cells were transferred into 14-ml polypropylene snap cap tubes (Falcon) and incubated with 10 U of recombinant gamma interferon (rIFN-␥; Life Technologies)/ml and/or 100 ng of lipopolysaccharide (LPS)/ml (Sigma [from Escherichia coli O127:B8]) for different time intervals as indicated. Macrophages were washed in phosphate-buffered saline (PBS) and incubated for 30 min with 1% fetal calf serum-0.1% NaN 3 in cold PBS (fluorescence-activated cell sorting [FACS] buffer). DCs were washed in PBS and preincubated in 10% normal mouse serum (Sigma) and 2.5 g of mouse Fc block (2.4G2; BD Pharmingen)/ml in FACS buffer for 30 min. This blocking step was essential to avoid binding of MAb to Fc receptors. Cells were then incubated for 30 min with (i) rat R-PE anti-mouse I-A/I-E (1:100, clone M5/114.15.2; BD Pharmingen), (ii) PE anti-mouse CD40 (1:100, clone 3/23; BD Pharmingen), or (iii) with the same concentration of PE-rat immunoglobulin G2a (IgG2a), isotype standard (clone R35-95; BD Pharmingen). DCs were coincubated with FITC-conjugated anti-mouse CD11c (1:200, clone HL3; BD Pharmingen) or with the same concentration of FITC-conjugated hamster IgG, group 1, isotype standard (G235-2356; BD Pharmingen). After being washed with cold PBS, cells were analyzed by flow cytometry.
Slc11a1 detection by flow cytometry. DCs, macrophages, and the control B-cell line WEH231 were fixed for 20 min on ice in 4% paraformaldehyde, washed in FACS buffer, and blocked in blocking buffer (PBS, 0.1% saponin, 5% milk [Marvel]) for 1 h. Cells were incubated for 2 h at ambient temperature with a rabbit polyclonal antibody (1:200) prepared (1) against recombinant fusion protein corresponding to amino acids 1 to 82 of murine Slc11a1 (a gift from C. Howard Barton, University of Southampton, Southampton, United Kingdom). This antibody recognizes a mature 90-to 100-kDa fully glycosylated Slc11a1 protein in transfected COS cells, as well as the 45-kDa precursor (1) . Cells were washed in PBS-0.1% saponin three times and then incubated with secondary Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes) at a 1/200 dilution for 2 h at ambient temperature in PBS-0.1% saponin-1% milk. Cells were then washed three times in PBS-0.1% saponin. After a final wash in PBS, cells were analyzed by flow cytometry.
Confocal microscopy. CD11c ϩ unstimulated DCs or DCs stimulated for 24 h with 10 ng of LPS/ml were isolated by using a MoFlo (Dako) high-performance cell sorter. Cells were blocked by using 10% mouse normal mouse serum and Fc block and then stained for 30 min on ice in FACS buffer with FITC-conjugated anti-mouse CD11c (1:200, clone HL3; BD Pharmingen) or the appropriate FITC hamster IgG, group 1, isotype standard (G235-2356; BD Pharmingen). After a sorting step, DCs were cytospun onto polylysine-coated slides to a density of 5 ϫ 10 4 /spot, air dried for 5 min, and fixed in 4% paraformaldehyde for 25 min. Single staining for Slc11a1 was performed as follows. Slides were washed three times in PBS-0.05% Tween (PBST) and blocked for 1 h at room temperature in PBS-0.1% Triton X-100-5% milk (Marvel) (blocking buffer). After three washes in PBST, the cells were incubated with polyclonal rabbit anti-mouse Slc11a1 (N-terminal antibody [1] at 1:200 dilution) in blocking buffer for 2 h at ambient temperature. This was followed by three washes in PBST and incubation with secondary Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes) at 1/400 dilution in blocking buffer for 2 h. Slides were washed three times in PBST, rinsed with PBS, air dried, and mounted (Vectashield). Cells were viewed with a Nikon Optiphot-2 epifluorescence microscope coupled to a Bio-Rad MRC 1000 confocal laser scanning attachment (Bio-Rad Laboratories, Ltd., Hemel Hempsted, United Kingdom). Images were collected by using Lasersharp 2000 software. For colocalization studies, slides were double stained for Slc11a1 (as described above) and early or late endosomal/lysosomal markers. Briefly, cells were blocked (as described above) and coincubated with polyclonal rabbit antimouse Slc11a1 (N-terminal antibody at a 1:200 dilution) and goat anti-EEA1 polyclonal antibody (1:100; Santa Cruz) or rat anti-Lamp1 MAb (1:100, clone 1D4B; Developmental Studies Hybridoma Bank, Iowa City, IA) in blocking buffer overnight at 4°C. After three washes in PBST, cells were incubated with secondary antibodies Alexa Fluor 594 goat anti-rat IgG (Molecular Probes) and Alexa Fluor 594 donkey anti-goat IgG (Molecular Probes) for Lamp-1 and EEA1 detection, respectively. Incubation was for 2 h in PBS-0.1% Triton X-100-1% milk. Slides were washed, mounted, and analyzed as described above.
TaqMan quantitative RT-PCR. DCs were stimulated for various time intervals with 1 g of LPS/ml prior to depletion by negative selection of Gr-1-positive cells as follows. Cells were incubated with biotinylated anti-mouse Ly-6G (Gr-1) (RB6-8C5; BD Pharmingen), followed by BD Imag Streptavidin Particles Plus-DM (BD Pharmingen), according to manufacturer's instructions. Macrophage contamination was minimized by harvesting nonadherent cells. This method of culture routinely yielded 75 to 85% CD11c ϩ cells by FACScan analysis (data not shown) prior to elimination of GR1 ϩ /CD11c Ϫ cells, which further improved CD11c ϩ purity. We did not use CD11c ϩ selection for Slc11a1 TaqMan analysis since we wanted to avoid the activation of CD11c ϩ cells through purification. The Gr-1-positive fraction was removed by using a BD IMagnet, the Gr-1-negative cells extracted in TRIzol (Invitrogen) and RNA pellets resuspended in RNase-free water. Prior to reverse transcription (RT), RNA was DNase treated by using DNA-free (Ambion, Austin, TX) according to the manufacturer's instructions, 1.6 g of oligo(dT) 15 was added, and the sample was denatured at 70°C for 10 min. RNA was reverse transcribed with 10 U of Super RT (HT Biotechnology, Ltd., Cambridge, United Kingdom) per g of total RNA, 1ϫx Super RT buffer, a 1 mM concentration of each deoxynucleotide triphosphate, and 40 U of RNaseOUT (Invitrogen) at 42°C for 40 min. Relative quantitation of specific cDNA species to rodent GAPDH (glyceraldehyde-3-phosphate dehydrogenase) endogenous control (Applied Biosystems) was conducted on the ABI 7700 (PE Applied Biosystems, Warrington, United Kingdom) using TaqMan chemistry and the comparative C T method with separate tubes. Sequences for primers and probes were as follows: Slc11a1, forward (5Ј-GCTG TCATGCAGGAGTTT-3Ј), reverse (5Ј-GCGCCATGATGCACGAA-3Ј), and probe (5Ј-ATGGCTTTGCTCATCCGGCCG-3Ј); and IL-10, forward (5Ј-GCC CAGAAATCAAGGAGCATT-3Ј), reverse (5Ј-GCTCCACTGCCTTGCTCTT ATT-3Ј), and probe (5Ј-AGGCGCTGTCATCGATTTCTCCCCT-3Ј). IL-12 reagents were purchased from Applied Biosystems. Relative quantification of signal per cell was determined by subtracting the C T for the target gene from the C T for GAPDH. The relative expression levels were compared to an internal control and are expressed as 2 Ϫ⌬⌬CT . Antigen-presenting cell assays. Ovalbumin (OVA)-specific DO11.10 or Leishmania homologue of the receptor for activated C kinase (LACK)-specific LMR7.5 (a gift from N. Glaichenhaus) T-cell hybridomas were plated in complete medium at 10 5 cells/well in 96-well U-bottom plates. 10S and 7.5R or MUT12 and WT3 pairs of transfected macrophage lines (see above) prestimulated with 25 U of IFN-␥/ml for 24 h were added at 0.5 ϫ 10 5 cells/well. Unstimulated or prestimulated (24 h, 100 ng of LPS/ml) DCs were used at 0.25 ϫ 10 5 cells/well. Chicken OVA peptide 323-339 (ISQAVHAAHAEINEAGR), albumin from chicken egg white (Sigma), or recombinant LACK protein (46) were added at the indicated concentrations in complete medium, and cells were stimulated for 24 h at 37°C in 5% CO 2 prior to harvesting the supernatants for the detection of IL-2 by enzyme-linked immunosorbent assay. As expected, the incubation of DCs or macrophages with antigen, or T cells alone with antigen did not generate IL-2 (data not shown).
Statistics. Unpaired, two-tailed Student t tests were used for between-group comparisons. Differences between experimental groups were considered significant for P values of Ͻ0.05.
RESULTS

Slc11a1
is expressed at mRNA level in DCs from congenic mice. Previous studies show that Slc11a1 is expressed at the mRNA level in macrophages from both wild-type and mutant mice (5, 15, 26, 37, 48). We used TaqMan RT-PCR to compare expression at the mRNA level in macrophage cell lines stably transfected with wild-type and mutant Slc11a1 and in DCs derived from wild-type and mutant mice on BALB and B10 genetic backgrounds (Fig. 1) . As with previous studies (15) , stimulation of macrophages with 10 U of IFN-␥/ml upregulated the expression of Slc11a1 at the mRNA level (Fig. 1A) . Macrophages stably transfected with wild-type Slc11a1 (7.5R) showed higher relative expression of Slc11a1 mRNA than macrophages stably transfected with mutant Slc11a1 (10S). However, stimulation of CD11C ϩ DCs derived from Slc11a1 wildtype C.D2-Vil6 bone marrow with 20 U of IFN-␥/ml did not increase expression of Slc11a1 mRNA (Fig. 1B) . These DCs did, however, show increased expression of Slc11a1 mRNA in response to 24 h of stimulation with 1 g of LPS/ml (Fig. 1B) . We therefore used stimulation with 1 g of LPS/ml in a more comprehensive comparison of Slc11a1 mRNA expression in DCs derived from pairs of congenic mice on BALB and B10 genetic backgrounds (Fig. 1C and D) . BALB background mice were more responsive to LPS stimulation than DCs derived from B10 background mice, but there was equivalent expression (P Ͼ 0.05) of Slc11a1 in DCs derived from Slc11a1 wild-type mice compared to mutant mice at all time points.
Slc11a1 protein is expressed in DCs and localizes to Lamp1-positive vesicles. To determine initially whether Slc11a1 protein was expressed in DCs, we compared FACScan profiles with bone marrow-derived macrophages using an anti-N-terminal Slc11a1 antibody (1). The binding of isotype control antibody to macrophages (Fig. 2B ) and unstimulated DCs (Fig.  2C) derived from B10.L-Lsh wild-type mice was equivalent, and similar levels of Slc11a1 expression (a six-to sevenfold increase in mean fluorescence intensity compared to the isotype control) were demonstrated in the two cell types. In contrast, the WEH231 B-cell line ( Fig. 2A) showed only a small shift (two-to threefold) in mean fluorescence intensity for the anti-Scl11a1 antibody compared to the isotype control. Previous studies showed that Slc11a1 localizes to Lamp1-positive late endosomes and lysosomes in macrophages (28, 44) and to granules of polymorphonuclear leukocytes (18, 20) . Using unstimulated DCs derived from B10.L-Lsh wild-type mice, we found that Slc11a1 also colocalizes with Lamp1-positive vesicles ( Fig. 2D to F) and not with CD11c at the surface (data not shown) or EEA1-positive early endosomes (Fig. 2G to I ). Slc11a1 protein was also expressed in DCs derived from B10 mice (data not shown) but did not completely colocalize with Lamp1-positive vesicles (or CD11c or EEA1). This is consistent with previous studies (49) showing that a proportion of the mutant protein is retained within the endoplasmic reticulum. Similar results were obtained with LPS-stimulated DCs (data not shown).
Influence of Slc11a1 on IL-12 and IL-10 mRNA transcription in DCs from congenic mice. Previous studies of infectious diseases in Slc11a1 congenic mouse strains have demonstrated differences in Th1:Th2 bias (i.e., IFN-␥ to IL-4 cytokine responses) in antigen-specific T-cell responses during the course of infection in vivo (31, 34, 38, 45) . Other studies (12) have demonstrated that the My-D88 and non-MyD88 pathway-induced IL-10 production by macrophages and DCs can suppress endogenous IL-12 p70, thereby inhibiting Th1 development. We hypothesize, therefore, that the difference in bias toward Th1 versus Th2 responses in vivo in Slc11a1 congenic mouse strains could be due to differences in endogenous IL-12 versus IL-10 induction in macrophages or DCs. Using TaqMan quantitative RT-PCR, we examined IL-12 and IL-10 mRNA levels in CD11c ϩ DCs derived from BALB and B10 background congenic mice after stimulation with LPS (Fig. 3) . DCs derived from Slc11a1 wild-type and mutant mice on BALB and B10 genetic backgrounds upregulated IL-12 mRNA responses to equivalent degrees (Fig. 3A and B) , peaking at 15 h poststimulation and returning to baseline at 36 h. DCs derived from B10 background mice made a more vigorous IL-10 response (Fig.  3D ) compared to BALB background mice (Fig. 3C) , with sustained expression in DCs derived from all mice at 36 h poststimulation. Since the outcome of the Th1 cell response in vivo might reflect the balance between endogenous IL-10 and IL-12 responses, we also calculated the ratios of IL-10 to IL-12 mRNA as a measure of the potential for inhibition of Th1 induction. This revealed a significant trend for higher IL-10: IL-12 ratios at baseline and 15 h after LPS stimulation in DCs ϩ DCs derived from bone marrow from wild-type (B10.L-Lsh) and mutant (B10) congenic mice on a B10 genetic backgrounds, unstimulated or stimulated with 1 g of LPS/ml for 15, 24, or 36 h (D). RNA was isolated and Slc11a1 expression was determined by using TaqMan quantitative RT-PCR. Relative quantification of signal per cell was determined by subtracting the C T for the target gene from the C T for GAPDH. Relative expression, measured as 2 Ϫ⌬⌬CT , is compared against an internal control (unstimulated 10S ϭ 1 in panel A; unstimulated C.D2-Vil-6 ϭ 1 in panel B; unstimulated C.D2-Vil6 DCs ϭ 1 for panels C and D). All bars on the graphs show the standard error of the mean (some are too small to be visible). None of the differences between DCs from congenic pairs of mutant versus wild-type mice in panels C and D were significant (P Ͼ 0.05). Similar results were obtained in two independent experiments for the comparisons in panels C and D.
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on February 21, 2013 by PENN STATE UNIV http://iai.asm.org/ derived from the Slc11a1 mutant than in DCs from wild-type mice ( Fig. 3E and F) . This bias in IL-10 response by DCs could contribute to the inhibition of Th1 responses in Slc11a1 mutant mice in vivo and therefore lead to a bias toward a Th2 response in these mice. Quantification of MHC class II and CD40 expression. One of the most consistent pleiotropic phenotypes in macrophages from Slc11a1 wild-type versus mutant mice has been the difference in expression of MHC class II (4, 31, 32, 51, 52). We therefore compared the expression of class II and CD40 expression in CD11c ϩ DCs derived from B10 background congenic mice after LPS stimulation. DCs derived from B10.L-Lsh wild-type mice showed enhanced upregulation of surface class II in response to LPS compared to DCs derived from B10 mutant mice (Fig. 4A and C) . In contrast, no differences were observed in the regulation of CD40 expression (Fig. 4B and  D) . The results for MHC class II from an independent experiment expressed quantitatively as the ratio of geometric mean fluorescence for LPS stimulated over unstimulated DCs (Table  1 ) demonstrated the significantly enhanced ability to upregulate class II over baseline levels in DCs derived from Slc11a1 wild-type mice compared to DCs derived from mutant mice at 15, 24, and 36 h.
Antigen-presenting cell assays. Differences in class II expression could contribute to differences in efficiency of antigen presentation to CD4 ϩ T cells. In addition, we showed previously (39) that functional wild-type Slc11a1 influences the processing of antigen for presentation to T cells. Although LPS enhances MHC class II expression and ability to stimulate primed T cells, it decreases antigen uptake and presentation of native proteins (50) . Accordingly, we observed a much-reduced capacity of LPS-stimulated DCs to process and present antigen to OVA-or LACK-specific CD4 T-cell lines compared to unstimulated DCs (data not shown). Therefore, in order to examine differences in antigen processing, the ability of CD11c ϩ DCs derived from Slc11a1 congenic mice to process antigen for presentation to T cells was examined using unstimulated DCs. As for stably transfected macrophage lines (39) , DCs derived from BALB background Slc11a1 congenic mice presented OVA peptide to the H-2 d -restricted OVA-specific DO11.10 T-cell hybridoma cells with equal efficiency (Fig. 5A ). In contrast, DCs derived from Slc11a1 wild-type mice consistently outperformed DCs derived from Slc11a1 mutant mice in the processing of OVA protein for presentation to DO11.10 T-cell hybridoma cells (for an example, see Fig. 5C ). A similar difference was observed in the ability of DCs derived from Slc11a1 wild-type mice to process and present LACK protein to the H-2 d -restricted LACK-specific T-cell hybridoma than DCs derived from Slc11a1 mutant mice (Fig. 5D ). As before (39), RAW264.7 macrophages stably transfected with Slc11a1 wild-type allele and activated with IFN-␥ were highly proficient at processing and presenting LACK protein to this T-cell hybridoma, whereas the antigen-presenting cell function of mutant transfectants was poor (Fig. 5B ). Similar differences were observed when the processing and presentation of LACK protein to LACK-specific T cells for a second pair (WT3 versus MUT12) (49) of separately derived wild-type and mutant stably transfected RAW264.7 macrophage cell lines were compared (data not shown).
DISCUSSION
Previous studies have implicated Slc11a1/SLC11A1 in regulating multiple infectious and autoimmune diseases (8, 9, 33) . The wide range of pleiotropic effects that this protein has on macrophage function has made it hard to determine the pri- ϩ DCs from wild-type (C.D2-Vil6; B10.L-Lsh) and mutant (BALB/c; B10) congenic mice on BALB (A and C) and B10 (B and D) genetic backgrounds. RNA was isolated from unstimulated (U/S) DCs and from DC stimulated for 15, 24, or 36 h with 1 g of LPS/ml. IL-12 and IL-10 expression was determined by using TaqMan quantitative RT-PCR. Relative quantification of signal per cell was determined by subtracting the C T value for the target gene from the C T for GAPDH. Relative expression, measured as 2 Ϫ⌬⌬CT , is compared against an internal control (unstimulated C.D2-Vil6 DC ϭ 1). The ratio of IL-10 to IL-12 is shown for BALB (E) and B10 (F) background mice. All bars on the graphs show the standard error of the mean (some are too small to be visible). Differences in ratios are significant at P ϭ 0.008 for unstimulated DCs and at P ϭ 0.0008 for DCs stimulated for 15 h in panel E and at P ϭ 0.028 for unstimulated DCs in panel F. Similar results were obtained in three independent experiments.
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on February 21, 2013 by PENN STATE UNIV http://iai.asm.org/ mary mechanisms that influence disease outcome in vivo. Nor do we know whether macrophages are always the primary cell type through which Slc11a1 exerts it influence. Polymorphonuclear leukocytes have also been shown to express Slc11a1 (18, 20) and could contribute to antimicrobial activity and proinflammatory responses in vivo. Here we report for the first time that Slc11a1 is also expressed in myeloid CD11c ϩ DCs and, like macrophages (4, 31, 32, 39, 51, 52) , similarly exerts pleiotropic effects on cytokine transcription, MHC class II molecule expression, and processing of protein antigens for presentation to T cells.
Several studies have indicated that, in addition to a T-cellindependent influence on innate immunity and early resistance to infection with L. donovani (13) , S. enterica serovar Typhimurium (42) , and Mycobacterium spp. (25, 27) , Slc11a1 also exerts an effect on Th1:Th2 bias in vivo (31, 34, 38, 45) . This includes influences on Th1:Th2 bias after primary infection with L. donovani (31) , serovar Typhimurium (38) , and M. bovis (34) , as well as an ability to bias the immune response to exogenous antigen delivered to the immune system using attenuated serovar Typhimurium AroA mutant as a vaccine vehicle (45) . Although these effects have previously been related to differences in the cytokine and chemokine milieu, MHC class II expression, and antigen processing after interaction of these pathogens with Slc11a1 wild-type or mutant macrophages, our demonstration that myeloid CD11c ϩ DCs from Slc11a1 wild-type mice versus mutant mice display a parallel range of pleiotropic effects could be important in light of the Table 1 . Similar results were obtained in three independent experiments for MHC class II; only one experiment was performed for CD40. a Results are expressed as the ratio of geometric mean fluorescence for LPSstimulated over unstimulated DCs. The mean ratios were determined for the four possible ratios for duplicate stimulated over duplicate unstimulated cultures. Stimulation was done with 100 ng of LPS/ml for 15, 24, or 36 h as indicated.
b The differences between the Slc11a1 mutant and wild-type DCs (P ϭ 0.006, 0.017, and 0.002 at 15, 24, and 36 h, respectively) were evaluated by using the Student t test. The results for MHC class II expression are representative of three independent experiments (see also Fig. 4 ) in which similar results were obtained. unique role played by DCs in initiating primary immune responses by stimulating immunologically naive T cells (3) . In the context of autoimmune disease such as type 1 diabetes in NOD mice, it is the wild-type allele at Slc11a1 that promotes a Th1 response and has been associated with disease (29, 33) . Given their enhanced ability to process protein antigens in the immature state and the bias toward IL-12 in the immature state and upon early activation, wild-type DCs could contribute to the initial priming of autoreactive T cells in type 1 diabetes. This would be consistent with studies demonstrating Slc11a1 expression at RNA and protein levels in pancreatic islets (8, 21) . Intriguingly, however, DCs are also the cells that prime CD25 ϩ CD4 ϩ regulatory T cells that suppress type 1 diabetes (47). It is of interest, therefore, that it was the protective effect of the mutant allele derived from C57BL/10 (B10) and bred onto the NOD background that first highlighted Slc11a1 as a putative candidate gene for type 1 diabetes (29). Our demonstration here of a reduced capacity to process antigen, a reduced ability to respond to activation signals in terms of MHC class II expression, and a bias toward IL-10 relative to IL-12 production by unstimulated or immature DCs is consistent with a possible role for immature DCs from Slc11a1 mutant mice in priming a protective regulatory T-cell response in relation to development of type 1 diabetes (16). A similar balance of roles for DCs in priming proinflammatory Th1 versus Th2 and/or regulatory T cells might also occur in humans, where the functional promoter polymorphism at SLC11a1 has two major alleles that drive high and low expression (43) . The high-expresser SLC11A1 allele is associated with human type 1 diabetes (23), whereas the low-expresser allele is associated with high IL-10 responses in peripheral blood mononuclear cells stimulated with LPS (2) and with protection from type 1 diabetes (7, 23) . Additional work will be required to further define the role of DC subsets from Slc11a1 wild-type and mutant mice in regulating type 1 versus type 2 or regulatory T-cell responses in relation to the important role of this gene in regulating susceptibility to infectious and autoimmune diseases.
The difference in the ability to process protein antigens in DCs from Slc11a1 mutant mice versus congenic wild-type mice is interesting in relation to the primary function of Slc11a1 as a proton-dependent divalent cation transporter localized to the membranes of late endosomes and lysosomes. Two functions that might influence the processing and presentation of antigens are (i) endocytosis and early endosomal fusion events involving, in particular, MHC class II-containing multivesicular bodies, and (ii) the role of divalent cation-dependent metalloproteinases in antigen processing. A role for Slc11a1 in promoting endosomal fusion events in well established, particularly in relation to the fusion of microbe-containing phagosomes with the late endosome/lysosome compartment (22, 28, 44) . Whether Slc11a1 similarly influences the delivery of protein antigens to late endosomes, lysosomes, or multivesicular bodies for processing has yet to be established. A possible role for Slc11a1 in regulating metalloproteinase activity lies at the core of the current debate as to whether Slc11a1 is a proton/divalent cation symporter that transports divalent cations out of the late endosomal lysosomal compartment along a proton gradient (30) or a proton/divalent cation antiporter that delivers divalent cations to this compartment against a proton gradient (24, 35, 36) . Our most recent data using yeast complementation (M. Techau, M. Seaman, and J. M. Blackwell, unpublished data) support our original observation using cRNAinjected frog oocytes (24) that Slc11a1 functions as an antiporter. A role for Slc11a1 in promoting metalloproteinasedependent antigen processing would be consistent with antiport function and is a testable hypothesis in further studies.
Here we have demonstrated that, in addition to its expression in macrophages and polymorphonuclear leukocytes, Slc11a1 is expressed in late endosomes and lysosomes of CD11c ϩ myeloid DCs, where it similarly exerts pleiotropic effects on cytokine transcription, MHC class II molecule expression, and the processing of protein antigens for presentation to T cells. These observations have important implications for future studies designed to determine how this important gene regulates susceptibility to both infectious and autoimmune diseases in humans. 
